Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06946225 · ClinicalTrials.gov registry record · Phase 1
ACTengine® IMA203 Combined With mRNA-4203
A Phase 1 study of Cutaneous Melanoma and Synovial Sarcoma, sponsored by Immatics US.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 4
- Study locations
NCT06946225 is a Phase 1 study of Cutaneous Melanoma and Synovial Sarcoma that is actively recruiting participants, run by Immatics US. The registered enrollment target is 15 participants, below the 367-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06946225, a Phase 1 study of Cutaneous Melanoma and Synovial Sarcoma, is actively recruiting participants, sponsored by Immatics US.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 4
- Study locations
Study Summary
This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).
Conditions Studied
Interventions
- BIOLOGICAL IMA203
- BIOLOGICAL mRNA-4203
Study Locations (4)
California
- University of California San Francisco - San Francisco
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-07-25 |
| Est. Completion | 2029-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06946225
The ClinicalTrials.gov registry entry for NCT06946225 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 367-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (96% lower). The listed sponsor is Immatics US, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cutaneous Melanoma appearing as the primary indexed condition, and to 2 interventions - of which IMA203 is the first listed.
NCT06946225 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06946225 about?
NCT06946225 is a clinical study titled "ACTengine® IMA203 Combined With mRNA-4203". This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).
What is the current status of trial NCT06946225?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2025-07-25. Estimated completion is 2029-08.
What conditions does trial NCT06946225 study?
This clinical trial studies the following conditions: Cutaneous Melanoma, Synovial Sarcoma.
What interventions are being tested in trial NCT06946225?
The interventions under investigation include: IMA203 (BIOLOGICAL), mRNA-4203 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06946225?
This trial is sponsored by Immatics US, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06946225 being conducted?
This trial has 4 study locations across California, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
-
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
RECRUITING · Phase 1
-
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.